Aesthetic 4 min read

Melanotan-2 — A Synthetic Melanocortin Agonist

A truncated cyclic analogue of α-MSH developed at the University of Arizona in the 1980s. A look at its melanocortin pharmacology and pigmentation effects for the research bench.

Melanotan-2 is a synthetic, cyclic, seven-residue analogue of α-melanocyte-stimulating hormone (α-MSH) developed by Hadley and colleagues at the University of Arizona during the 1980s. It was designed as a research tool to probe melanocortin signalling — and the fact that it pigments skin without UV exposure was one of the observations that made it famous (and, eventually, recreationally misused).

It is not an authorised medicine and the MHRA has issued repeated public warnings about the recreational sale of “tanning injections”. The clinical-pharmacology literature is nevertheless substantial and worth unpacking for legitimate laboratory research.

What it is

The native α-MSH peptide is a 13-residue hormone derived from proopiomelanocortin (POMC). Hadley's group truncated it to its minimal active core and cyclised the sequence to lock the bioactive conformation, producing MT-II. The cyclisation makes the molecule metabolically more stable than linear α-MSH and increases its receptor affinity by an order of magnitude.

The receptor targets are the melanocortin receptors (MC1R, MC3R, MC4R, MC5R — MC2R is the adrenocortical ACTH receptor and is largely spared). MT-II is a non-selective agonist across MC1R, MC3R, MC4R and MC5R, which is the source of both its effects and its side-effects.

Mechanism

The receptor breakdown matters because each receptor maps to a different physiological output:

MC1R (skin, immune cells). Agonism stimulates eumelanin production in cutaneous melanocytes — the "tanning" effect. The pigmentation is real, dose-dependent, and persists for months until melanocyte turnover replaces the pigmented cells.
MC3R / MC4R (central, hypothalamic). Agonism drives reduced food intake (the MC4R-knockout phenotype is severe obesity). MC4R is also implicated in central erectile-response pathways, which is why PT-141 / bremelanotide — a closely-related linear analogue — became a sexual-function therapeutic.
MC5R (sebocytes, exocrine). Agonism has been linked to changes in sebum production and sweat-gland activity.

The "everything at once" agonist profile is the central limitation: unlike PT-141 (MC4R-skewed) or the selective MC1R agonists in development, MT-II hits everything in the receptor family in roughly proportional measure at typical research doses.

What the literature shows

The most-cited findings:

Pigmentation. Multiple human studies (Dorr et al., 1996; subsequent observational work) confirm that MT-II produces dose-dependent skin darkening without UV exposure. The mechanism is classical MC1R agonism on melanocytes.
Erectile function. A randomised phase-1/2 trial published in the early 2000s reported significant improvement in erectile function in psychogenic ED, mediated via MC4R agonism. This effect line eventually led to PT-141 / bremelanotide (Vyleesi, approved 2019 for HSDD in premenopausal women).
Appetite suppression. Less clinically prominent but pharmacologically robust — reflects MC4R agonism on hypothalamic appetite centres.

Adverse-effect profile

The most commonly reported acute effects in research-grade studies and observational reports:

Nausea and flushing, typically in the first hour after administration. Tends to attenuate with continued exposure.
Increased melanocytic naevi. Multiple case reports describe darkening or proliferation of moles. Long-term dermatological surveillance is the obvious follow-up question.
Spontaneous erections / sexual arousal. Direct consequence of central MC4R activation. Dose-dependent and predictable but a real consideration in any study design.

What we do not have are robust long-term safety data — particularly on cumulative pigmented-lesion burden — because no large prospective cohort study has been completed.

Half-life and stability

MT-II's plasma half-life in animal models is short, on the order of ~1 hour after subcutaneous administration. The biological effect (pigmentation) persists much longer than the plasma concentration because the effect operates on melanocyte gene expression rather than moment-to-moment receptor occupancy.

Lyophilised, MT-II is stable at room temperature for short periods and indefinitely at -20 °C. Reconstituted in bacteriostatic water, refrigerated stability is typically rated 30 days.

Quality

Because MT-II is short and heavily modified (acetylated N-terminus, unnatural amino acid Nle, D-Phe, side-chain-to-side-chain cyclisation), synthesis can produce a wider variety of side-products than for standard linear peptides. Truncated, isomerised or non-cyclised contaminants all behave differently at the melanocortin receptors and confound experiments. Pharma Tides supplies MT-II at >99% HPLC purity with batch ESI-MS and a signed COA on the product page.